arrow
M

María-Victoria Mateos

University of Calabria
H指数:108
被引数:5.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

作者更正:FcRH5×CD3 双特异性抗体 cevostamab 在复发或难治性多发性骨髓瘤中的研究:一项1期临床试验

2026-10-200
OAAI
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

FcRH5×CD3双特异性抗体塞沃司单抗在复发或难治性多发性骨髓瘤中的应用:一项I期临床试验

2026-07-220
OAAI
Study of post-translational modifications of p53 in multiple myeloma

多发性骨髓瘤中p53的翻译后修饰研究

2026-07-170
OA
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)

新诊断多发性骨髓瘤维持治疗格局的变化:欧洲骨髓瘤网络(EMN)的系统评价与网络荟萃分析

2026-06-180
OAAI
Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival

多发性骨髓瘤患者单采产品中的可测量残留病评估:与生物学、缓解深度和生存期的相关性

2026-06-180
PRE
European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B-Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community-Based Centers and for Outpatient Step-Up Dosing

欧洲关于将接受B细胞成熟抗原双特异性抗体治疗的多发性骨髓瘤患者护理从学术医院过渡到社区医疗中心并实施门诊剂量递增的建议

2026-05-140
OAAI
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial

Ciltacabtagene autoleucel在高风险冒烟型多发性骨髓瘤中的应用:CAR-PRISM二期临床试验

2026-04-200
OAAI
Enhanced dynamic risk stratification of smoldering multiple myeloma

增强的冒烟性多发性骨髓瘤动态风险分层

2026-03-011
OA
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study

Alnuctamab,一种靶向B细胞成熟抗原的双价T细胞结合剂,用于复发或难治性多发性骨髓瘤患者:一项1期首次人体研究的成果

Leukemia
IF13.4
2026-01-070
OAAI
Impact of the kinetics of circulating anti-BCMA CAR-T cells and normal lymphocytes on the outcome of MM patients

循环抗BCMA CAR-T细胞和正常淋巴细胞动力学对MM患者预后的影响

2025-12-280
OAAI
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Teclistamab联合Daratumumab治疗复发或难治性多发性骨髓瘤

2025-12-015
PRE
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network

BCMA-和GPRC5D靶向免疫疗法在多发性骨髓瘤中的序贯治疗:欧洲骨髓瘤网络实用指南

2025-11-250
OAAI
Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish society of laboratory medicine and the Spanish society of hematology and hemotherapy. Part III: clinical and analytical recommendations for the study of monoclonal gammopathies by MALDI-TOF mass spectrometry

Agulló, C.; Puig, N.; Varo, N.; Iglesias, M.Á.; Mugueta, C.; Pello, R.; Paiva, B.; Martínez-López, J.; Castro, S.; Cárdenas, M.C.; 等. 临床实验室中单克隆丙种球蛋白病的检测建议。西班牙临床实验室医学学会与西班牙血液学及血液治疗学会的共识。第三部分:利用MALDI-TOF质谱法检测单克隆丙种球蛋白病的临床与分析建议。Clin. Chem. Lab. Med. 2025. [Google Scholar] [CrossRef] [PubMed]

2025-11-011
PRE
Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years

ADMYRE随机Ⅲ期研究:评估普利地芬联合地塞米松与单用地塞米松治疗复发/难治性多发性骨髓瘤的疗效,结果针对年龄<75岁的患者群体。

Cancers
IF4.4
2025-10-290
OAAI
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform

基于EMN–HARMONY联盟平台的机器学习风险分层策略用于多发性骨髓瘤:见解

2025-10-090
OAAI
Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma

来自MonumenTAL-1研究的talquetamab在复发/难治性多发性骨髓瘤患者中细胞因子释放综合征的表征与管理

2025-10-020
OAAI